Physician profile
Thomas Hunter Lindsey
NPI 1841853108
$2,414.50
in general payments reported to CMS, 2019-2025
30 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.95 · 2023: $328 · 2024: $924 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $581.91 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $332.33 | 2024-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $327.52 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $138.83 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.08 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $104.03 | 2023-2025 | Jardiance, Kisunla, Mounjaro |
| Novo Nordisk INC | $82.71 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $76.74 | 2023-2025 | |
| Ibsa Pharma INC. | $67.06 | 2024 | Licart, Tirosint, Flector |
| Pfizer INC. | $61.53 | 2024 | |
| Abbvie INC. | $50.20 | 2024-2025 | |
| Tris Pharma INC | $48.23 | 2023-2024 | Dyanavel Xr |
| Esperion Therapeutics, INC. | $44.36 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $40.47 | 2024 | Veozah |
| Depuy Synthes Sales INC. | $34.30 | 2024 | Monovisc |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.38 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $28.77 | 2022 | |
| Amneal Pharmaceuticals LLC | $26.65 | 2025 | Unithroid |
| Pacira Pharmaceuticals Incorporated | $25.91 | 2023 | Iovera |
| Vericel Corporation | $24.85 | 2025 | Maci |
| Janssen Pharmaceuticals, INC | $21.81 | 2025 | Spravato |
| Bioventus LLC | $19.11 | 2023 | Durolane |
| Ossur Americas, INC. | $18.55 | 2025 | |
| Inspire Medical Systems, INC. | $17.59 | 2024 | Inspire |
| Galderma Laboratories, L.P. | $14.52 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.01 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $13.50 | 2025 | Voquezna |
| Aveo Pharmaceuticals, INC. | $12.18 | 2022 | |
| Axsome Therapeutics, INC. | $11.65 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lindsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.